Pulmonary embolism (PE) is a life-threatening condition that is difficult to diagnose in several patients. This is because clinical signs of PE are neither sensitive nor specific. In elderly patients, misdiagnosis of PE is a frequent event. The USFDA-approved PCSK9 class of inhibitors can lower LDL levels in the body and prevent heart attacks or strokes.
These drugs can effectively prevent the formation of emboli and their associated cardiovascular complications if used appropriately. Join expert cardiologists Dr. Hemang Baxi and Dr. Tejas V Patel to discuss “ A Case-based Discussion on Pulmonary Embolism and Use of PCSK-9-Inhibitors ” on 4 th July 2022, 3:00 PM IST onwards.
